Alexion has "clearly raised the treatment bar" in paroxysmal nocturnal hemoglobinuria with this morning's ALXN1210 data in a "fashion that few expected," Piper Jaffray analyst Christopher Raymond tells investors in a research note. On efficacy and safety, the data look like a "huge win across the board" as '1210 met all primary and secondary endpoints in showing non-inferiority to Soliris, but more importantly, showed numerical superiority across the board, Raymond writes. The analyst would be an "aggressive" buyer of Alexion shares on today's open. He has an Overweight rating on Alexion with a $170 price target.